{"organizations": [], "uuid": "2dcd2e7d9184f44073eca57b74e232e529239d5c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.prnewswire.com", "main_image": "http://photos.prnewswire.com/prnvar/20130307/600769", "site_section": "http://rss.prnewswire.com/industry/entertainment/", "section_title": "PR Newswire: Entertainment & Media", "url": "http://www.prnewswire.com/news-releases/global-breast-cancer-therapeutics-2015-pipeline-market-analysis-to-2023-300164630.html", "country": "IT", "title": "Global Breast Cancer Therapeutics 2015: Pipeline Market Ana", "performance_score": 0, "site": "prnewswire.com", "participants_count": 1, "title_full": "Global Breast Cancer Therapeutics 2015: Pipeline Market Ana", "spam_score": 0.0, "site_type": "news", "published": "2015-10-22T15:11:00.000+03:00", "replies_count": 0, "uuid": "2dcd2e7d9184f44073eca57b74e232e529239d5c"}, "author": "Research and Markets", "url": "http://www.prnewswire.com/news-releases/global-breast-cancer-therapeutics-2015-pipeline-market-analysis-to-2023-300164630.html", "ord_in_thread": 0, "title": "Global Breast Cancer Therapeutics 2015: Pipeline Market Ana", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "DUBLIN , Oct.   Research and Markets ( http://www.researchandmarkets.com/research/2cr7j9/breast_cancer ) has announced the addition of the \"Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023\" report to their offering. Based on clinical phases, the breast cancer therapeutics: pipeline analysis market has been segmented into three major categories: phase I drug candidates, phase II drug candidates, and phase III drug candidates. \nTabular representation for phase I drug candidates and phase II drug candidates has been provided, which summarizes information about promising drug candidates under clinical trials and associated conditions, sponsors and collaborators, primary outcome measure, time frame, and status about designated safety issue. \nThe phase III drug candidates section is further differentiated into various key molecules that are expected to give promising results. These molecules include Palbociclib (PD-0332991) + Fulvestrant, NK105, BKM120, NKTR-102, Neratinib, Olaparib, DOXIL, ABP 980, CT-P6, and Trastuzumab Emtansine + Pertuzumab. \nCommercial analysis for all these molecules is provided by forecasting the anticipated market revenue from the expected year of commercialization until 2023. Compound annual growth rate (CAGR %) for each of these molecules is also provided for the period from the expected commercialization year to 2023.\nA list of recommendations has been provided for new entrants as well as existing market players to assist in taking strategic initiatives in a bid to establish a strong pipeline for breast cancer therapeutic drugs. The report also profiles major players in the breast cancer therapeutics: pipeline analysis market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. \nMajor players profiled in this report include AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and Sanofi. \nKey Topics Covered: \nChapter 1 Introduction\nChapter 2 Executive Summary \nChapter 3 Market Overview\nChapter 4 Global Breast Cancer Therapeutics: Pipeline Analysis, by Drugs (Phase III) \nChapter 5 Recommendations\nChapter 6 Company Profiles \n- AstraZeneca plc\n- Eisai Co., Ltd. \n- Eli Lilly and Company \n- F. Hoffmann-La Roche Ltd. \n- GlaxoSmithKline plc \n- Novartis International AG \n- Pfizer, Inc. \n- Sanofi \nFor more information visit \nhttp://www.researchandmarkets.com/research/2cr7j9/breast_cancer \nMedia Contact: \nLaura Wood , +353-1-481-1716, press@researchandmarkets.net \n \n\nSOURCE Research and Markets\n\n\nRELATED LINKS\nhttp://www.researchandmarkets.com", "external_links": [], "published": "2015-10-22T15:11:00.000+03:00", "crawled": "2015-10-22T15:20:18.164+03:00", "highlightTitle": ""}